

Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC

Thomas Karsten Kilvaer^{1, 2}

Mehrdad Rakaee^{2, 3}

Turid Hellevik^{1, 2}

Jørg Vik²

Luigi De Petris⁴

Tom Donnem^{1, 2}

Carina Strell⁴

Arne Ostman⁴

Lill-Tove Rasmussen Busund^{3, 5}

Inigo Martinez-Zubiaurre²

1 Department of Oncology, University Hospital of North Norway, Tromsø, Norway

2 Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway

3 Institute of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway

4 Department of Oncology-Pathology Cancer Center Karolinska, Karolinska Institutet, Stockholm Sweden

5 Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway

Corresponding author and reprints:

Thomas K. Kilvaer, MD PhD

Department of Oncology, University Hospital of North Norway

9038 Tromsø, Norway

Telephone: +47 776 26 765/+47 905 24 635

Fax: +47 77626779

E-mail: kilvaer@gmail.com kilvaer@gmail.com


Supplementary table 1: Co-expression of PDGFR- α and PDGFR- β as predictors of A) disease-specific survival in a Norwegian cohort of 553 stage I-IIIB NSCLC patients (307 and 239 in the SCC and ADC subgroups respectively) and B) overall survival in a Swedish cohort of 367 stage I NSCLC patients (109 and 209 in SCC and ADC subgroups respectively, log-rank test)

A) Norwegian cohort					B) Swedish cohort				
N(%)	5 Year	Median	HR(95%CI)	P	N(%)	5 Year	Median	HR(95%CI)	P
Overall cohort									
0.012					0.018				
α -/ β -	247(45)	62	190	1	157(43)	56	76	1	
α -/ β +	112(20)	43	47	1.57(1.09-2.26)	72(20)	58	68	1.01(0.71-1.44)	
α +/ β -	62(11)	59	NA	1.03(0.67-1.59)	49(13)	67	87	0.9(0.6-1.34)	
α +/ β +	88(16)	68	235	0.81(0.55-1.18)	61(17)	70	NA	0.52(0.37-0.74)	
Missing	44(8)				28(8)				
Squamous cell carcinoma									
0.059					0.068				
α -/ β -	133(43)	64	NA	1	44(40)	45	52	1	
α -/ β +	67(22)	50	64	1.38(0.82-2.33)	26(24)	46	58	1.04(0.57-1.91)	
α +/ β -	29(9)	74	NA	0.69(0.36-1.32)	14(13)	79	99	0.45(0.23-0.87)	
α +/ β +	54(18)	76	235	0.61(0.36-1.02)	16(15)	69	112	0.51(0.27-0.99)	
Missing	24(8)				9(8)				
Adenocarcinoma									
0.051					0.026				
α -/ β -	113(47)	59	190	1	94(45)	62	84	1	
α -/ β +	42(18)	33	41	1.89(1.12-3.19)	37(18)	68	103	0.92(0.56-1.53)	
α +/ β -	32(13)	48	57	1.33(0.74-2.39)	24(11)	66	80	1.06(0.58-1.94)	
α +/ β +	32(13)	57	98	1.08(0.61-1.93)	39(19)	74	NA	0.42(0.26-0.67)	
Missing	20(8)				15(7)				

Abbreviations: PDGFR, platelet-derived growth factor receptor; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; ADC, adenocarcinoma.

Supplementary figure 1: Survival curves for the co-expression of PDGFR α and PDGFR β in the overall cohorts and in the SCC and ADC subgroups for the Norwegian cohort (A, C and E) and the Swedish cohort (B, D and F)

Abbreviations: PDGFR, platelet-derived growth factor receptor; SCC, squamous cell carcinoma; ADC, adenocarcinoma.



Supplementary figure 2: Survival curves for the co-expression of PDGFR α and PDGFR β in Norwegian cohort according to increasing pStage

Abbreviations: PDGFR, platelet-derived growth factor receptor; SCC, squamous cell carcinoma; ADC, adenocarcinoma.

